Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MYCOSIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,081 records · Page 60Linked to original sources

Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with ciclosporin A: a word of caution.

A patient with mycosis fungoides in the tumor stage was treated with ciclosporin A orally in daily doses of 5 mg/kg body weight for 5 weeks. Three weeks after cessation of treatment the patient died with dissemination of the cutaneous lymphoma to the lungs, myocardium, liver, pancreas, kidneys, adrenals, and stomach. Treatment with ciclosporin A may have contributed to the death of this patient.

Cyclosporins↗

Mycosis fungoides and Sézary's syndrome show distinct histomorphological features.

A light microscopic investigation of skin biopsy specimens from 10 patients with plaque stage mycosis fungoides (MF) and from 6 with Sézary's syndrome (SS) was carried out according to the defined histologic criteria, for the purpose of detecting some morphological characteristics of these diseases for their histological differentiation. This study revealed that some histomorphological differences regarding the epidermal and dermal changes, epidermotropism and the cellular infiltrate existed between MF and SS, and that these diseases were two distinct entities showing differences not only from a clinical and hematologic but also from the histological viewpoint.

Adult↗

Blood lymphocyte subpopulations studied with monoclonal antibodies in aleukaemic stages of mycosis fungoides.

Peripheral blood lymphocytes from 21 patients with aleukaemic stages of mycosis fungoides were studied with monoclonal T cell antibodies. Patients with erythematous eruptions or infiltrated plaques (group I) had a higher percentage of OKT4+ cells than patients with a tumorous stage (group II) or normal subjects (p = 0.05). OKT8+ cells were decreased in group I patients whereas in group II they were usually normal or increased (p less than 0.02). These data indicate that with advancing stage of the disease a different pattern of imbalance of T-cell subsets is being established.

Adult↗

Precautions for personnel applying topical nitrogen mustard to patients with mycosis fungoides.

An increased awareness among staff personnel of the potential damaging effects of cytostatic drugs has lead us to take specific precautions when nitrogen mustard is used as topical therapy in mycosis fungoides. This report deals with the risks involved in using nitrogen mustard, and how to take steps against such risks. The exposure of healthy staff personnel to potential risks from cytostatic drugs can, and should, be avoided.

Accidents, Occupational↗

Treatment of mycosis fungoides with heat-killed BCG and cord factor.

6 patients with mycosis fungoides in different stages of the disease were successfully treated with intralesional injections of 1% mineral oil emulsions of killed BCG and cord factor, and/or topical application of an ointment containing killed BCG and cord factor.

Administration, Topical↗

PUVA treatment in mycosis fungoides.

2 patients with mycosis fungoides at the plaque stage were treated with oral methoxalen and UVA irradiation. 3 months later both developed the skin tumours with highly malignant histological picture. In 1 patient at the tumour stage the skin tumours were spreading during the PUVA treatment. 3 patients at the first or eczematoid stage cleared completely or partially by PUVA treatment.

Adult↗

Delayed-type hypersensitivity in patients with mycosis fungoides.

Cell-mediated immune reactivity was studied in 23 patients with mycosis fungoides and Sézary's syndrome by a semi-quantitative 2,4-dinitrochlorobenzene (DNCB) sensibilization test and the reaction to intracutaneous microbial antigens. Anergy to DNCB was observed in 8 patients, 5 had a markedly depressed DNCB score, 6 showed negative reactions to the microbial antigens. A defect in antigen recognition is suggested.

Adult↗

A study on leukocytes phospholipid composition in mycosis fugoides.

Leucocyte phospholipids composition was determined in 16 patients with mycosis fungoides and 20 healthy controls. Statistically significant differences namely, an increase in phosphatidylcholine and diphosphatidylglycerol and a decrease in phosphatidylserine and phosphatidylinositol concentrations between patients and healthy subjects were observed.

Cardiolipins↗

Is mycosis fungoides an "immunoma'?

New knowledge of the function and biological behaviour of the cells of the lymphocytic system justifies a critical reappraisal of the nature and origin of mycosis fungoides (MF). The fact that in MF the immune response remains active during the whole course of the disease distinguishes it from other malignant processes. On the basis of the well-known fact that chronic stimulation of the immunological system may lead to tumour formation, the hypothesis is stressed that MF may be an "immunocytoma' or 'immunoma'. New findings indicate that immunological stimulation of lymphocytes may lead to the formation of endogenous oncogenic viruses. All these questions should be investigated in as many centres as possible.

Animals↗

DNA content analysis by flow cytometry and cytogenetic analysis in mycosis fungoides and Sézary syndrome.

Flow cytometric (FCM) analysis of DNA content was performed on 82 lymph node and peripheral blood specimens from 46 patients with mycosis fungoides and the Sézary syndrome. Overall, 32 of the 46 patients (70%) had aneuploidy detected by FCM. Aneuploidy was present in 63% of the patients at the time of diagnosis before systemic therapy. In these patients, aneuploidy was frequently detected in blood and lymph node specimens scored as negative by cytology and histology, suggesting that unsuspected extracutaneous dissemination is present in many patients at the time of diagnosis. Direct comparison with Giemsa-banded cytogenetic studies showed an excellent correlation of FCM results and cytogenetic chromosome number. However, FCM frequently detected a larger fraction of aneuploid cells, and mitogen-stimulation studies suggest this is the result of preferential stimulation of normal lymphocytes by phytohemagglutinin. Thus, mitogens with a preference for malignant T cells, such as staphylococcal protein A, should be used for cytogenetic analysis of malignant T-cell disorders. At diagnosis, some histologically positive specimens contained only diploid cells by FCM and cytogenetic analysis. These patients had a more indolent clinical course than patients with aneuploidy. Aneuploidy was detected by FCM as either wide G(1) or as discrete aneuploid peaks. The presence of aneuploidy at any time in the clinical course implied a poor prognosis. Discrete hyperdiploid peaks were associated with large cell histology, early relapse, and aggressive clinical course. The development of hyperdiploidy at relapse was documented in four patients and was associated with a transition to large cell histology and a poor prognosis. Similar studies may elucidate differences in natural history and mechanism for transition in histology in other lymphomas and solid tumors.

Chromosome Banding↗

Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.

Using a panel of monoclonal antibodies and rabbit heteroantisera, we have studied the cell surface markers of peripheral blood (PB) Sezary cells from six patients with mycosis fungoides or Sezary syndrome, disease grouped within the spectrum of cutaneous T cell lymphomas (CTCL). Furthermore, we have studied two cell lines (Hut 78 and Hut 102) derived from malignant Sezary T cells from CTCL patients. The monoclonal antibody 3A1 defines a major human PB T cell subset (85% of PB T cells) while the antigen defined by the monoclonal antibody 4F2 is present on a subset (70%) of activated PB T cells and on circulating PB monocytes. In contrast to normal subjects in whom 60-70% of circulating PB mononuclear cells were 3A1(+) T cells, PB mononuclear cells from six CTCL patients studied had an average of only 10.6+/-3.2% 3A1(+) T cells. Whereas 85% of E-rosette positive cells from normal individuals were 3A1(+), virtually all E-rosette positive T cells from the Sezary patients were 3A1(-). Two patients with high numbers of circulating Sezary T cells had both aneuploid and diploid PB T cell populations present; after separation of PB T cells into 3A1(+) and 3A1(-) cell suspensions, all 3A1(-) cells were found to be aneuploid. In contrast to normal resting PB T cells which were 4F2(-), all PB Sezary cells were 4F2(+), suggesting a state of activation. The 3A1 antigen was on a variety of acute lymphoblastic leukemia T cell lines (HSB-2, RPMI-8402, MOLT4, CEM) but was absent on the Hut 78 and Hut 102 Sezary T cell lines. Using rabbit anti-human T and anti-human Ia (p23, 30) antisera, we found that all malignant Sezary PB cells tested were killed by anti-T cell antiserum plus complement but not by anti-Ia plus complement. In contrast, Sezary cell lines Hut 78 and 102, were killed by both anti-T cell antiserum and anti-Ia plus complement. Similar to 3A1(-) normal PB T cells, 3A1(-) Sezary PB T cells proliferated poorly to phytohemagglutinin and concanavalin A. However, 3A1(-) Sezary T cells were able to provide T cell help towards pokeweed mitogen-induced in vitro B cell immunoglobulin synthesis, an immunoregulatory function limited to 3A1(+) T cells in normal subjects.Thus, the 3A1 antigen is present on 85% of normal PB T cells, and on most T-acute lymphoblastic leukemia lines tested; in contrast the 3A1 antigen is not present on the majority of circulating malignant Sezary PB T cells nor on T cell lines derived from malignant Sezary T cells. The lack of expression of the 3A1 antigen may be associated with malignant transformation of T cells in CTCL and may be an important marker for tracing the clonal origin of the malignant Sezary T cell.

Adult↗

The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients.

For nearly two decades it has been suspected that the cutaneous T cell lymphoma, mycosis fungoides (MF), and its leukemic variant, the Sézary syndrome, are caused by the human T lymphotropic virus (HTLV-I/II). Arguments against this concept included the finding that only a small number of MF patients have antibodies to HTLV-I/II and that attempts to detect proviral sequences by mere Southern hybridization of extracted DNA usually met with failure. However, we have reported repeatedly that HTLV-like particles emerge in blood mononuclear cell (PBMC) cultures of practically all patients with this disease. In several instances, the particles were identified as HTLV by immunoelectron microscopy as well as biomolecular analysis. With the assumptions that the virus in MF patients may have become detection by Southern hybridization alone, the extracts of freshly isolated PBMC of 50 consecutive patients were subjected to combined PCR/Southern analysis. Here we report the presence of HTLV pol and/or tax proviral sequences in 46 out of 50 (92%) of the patients tested. In addition, five of the patients, who lacked antibodies to HTLV-I/II structural proteins, were found to be seropositive for tax. It thus seems reasonable to conclude that MF/Sézary syndrome is an HTLV-associated disease and that lack of an immune response does not preclude infection with this type of virus.

Adult↗

Gastrointestinal complications of mycosis fungoides.

Mycosis fungoides (MF) is an uncommon T-cell lymphoma which characteristically involves the skin. Two patients with MF are described who developed fatal complications secondary to involvement of the gastrointestinal tract. One developed malabsorption due to small intestinal involvement; the other had a massive haemorrhage from an ulcerated nodule of tumour in the stomach. The potential for extracutaneous spread is discussed, and it is emphasized that bowel infiltration should be considered in any patient with MF who develops gastrointestinal symptoms or complications.

Humans↗

Clinical and immunological evaluation of 5 cases of mycosis fungoides in advanced stages.

Five patients with mycosis fungoides, hospitalized in the Division of Radiotherapy and Medical Oncology of the Ospedale Civile, Pordenone, from January 1975 to December 1978, were studied and treated as non-Hodgkin lymphomas. All patients had evidence of disseminated disease: 3 with bone marrow infiltration, 1 with splenic involvement and 1 with lymph node involvement. Three patients were treated with CVP, resulting in 2 complete remissions that lasted 18 months and 1 PR greater than 50% maintained for 7 months. One patient was treated with ABVD with a PR greater than 50% maintained for 10 months. The last patient was treated with prednisone and then with CV, but expired from pulmonary embolism after 1 cycle. Lymphocyte function, using E and EAC rosette and PHA, was evaluated before therapy in all patients: in the 2 patients who obtained a CR, an improvement in T-lymphocyte function was noted after therapy. The chromosome pattern of peripheral blood lymphocytes was altered before therapy in only one patient. Even if the follow-up period is still relatively brief, the duration of the 2 complete remissions must be stressed. In addition, a strict correlation between T-lymphocyte function and response to therapy was revealed in our study.

Adult↗

VM 26 in advanced mycosis fungoides.

Five consecutive patients with progressive extracutaneous stage IV mycosis fungoides (MF) were treated with VM 25, 100 mg/m2 i.v., for at least 3 cycles. All patients had been extensively pretreated and in particular with vinca alkaloids. Two partial responses of 5 and 9+ months duration and 1 minimal response of 5 months duration were obtained. Transient myelosuppression was encountered in all patients. These preliminary results should encourage further exploration of VM 26, even in less advanced MF.

Adult↗

A canine cutaneous lymphoproliferative disease resembling mycosis fungoides in man.

A dog with a lymphoproliferative disease resembling mycosis fungoides in man, the second reported canine case, had slowly progressive, multicentric cutaneous nodules and plaques. Nearly half the body surface was involved. The lesions consisted of multiple, flat, infiltrative, cutaneous tumors composed of heterogeneous, pleomorphic cells, some of which resembled histiocytes or activated lymphocytes. Intracutaneous foci of tumor cells and numerous tumor cells with bizarre convoluted nuclei were distinctive features that permitted the lesions to be distinguished from other non-epithelial cutaneous neoplasms.

Animals↗